RxDoctor Payments Data

Nicole Monroig

Family · Atlantis, FLNPI 1205208063

Payments from drug & device makers

$6,238in general payments, 2019–2025

Across 313 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$741
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$568
  • Takeda Pharmaceuticals U.S.A., Inc.$437
  • Bristol Myers Squibb$389
  • Lilly USA, LLC$268
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,10298%
  • Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,238 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$43,603
Medicare patients
271
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine14$4,999
ClenpiqSod Picosulf/Mag Ox/Citric Ac23$3,914
SutabSod Sulf/Pot Chloride/Mag Sulf19$3,031
Famotidine200$2,527
Omeprazole121$1,215
Colestipol Hcl14$1,054
Pantoprazole Sodium72$1,022
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$756
Sucralfate19$613
Dicyclomine Hcl20$455
Ondansetron OdtOndansetron17$329
Ondansetron Hcl14$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$76$3,91423 claims
Braintree Laboratories, Inc.Sutab$140$3,03119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →